Keyphrases
Advanced Biliary Tract Cancer
40%
Advanced or Metastatic
20%
Antitumor Activity
20%
Biliary Cancer
100%
Biliary Tract Cancer
60%
Cancer Study
100%
Chemotherapy
20%
Cholangiocarcinoma
20%
Combination Chemotherapy
20%
Complete Response
20%
Confidence Interval
60%
Disease Control Rate
20%
First-line Therapy
20%
Gallbladder Cancer
100%
Gemcitabine
100%
Locally Advanced
20%
Median Overall Survival
20%
Median Progression-free Survival
20%
Median Survival
20%
Neutropenia
20%
Objective Response Rate
20%
Oxaliplatin
100%
Palliative Treatment
20%
Phase II Study
20%
Phase II Trial
100%
Poor Response
20%
Previously Untreated
20%
Response Rate
20%
Stable Disease
20%
Thrombocytopenia
20%
Medicine and Dentistry
Antineoplastic Activity
20%
Bile Duct Cancer
100%
Biliary Tract Cancer
100%
Chemotherapy
20%
Cholangiocarcinoma
20%
Combination Chemotherapy
20%
Disease
40%
Gallbladder Cancer
100%
Gemcitabine
100%
Malignant Neoplasm
100%
Neutropenia
20%
Overall Survival
20%
Oxaliplatin
100%
Phase II Trials
100%
Progression Free Survival
20%
Symptomatic Treatment
20%
Thrombocytopenia
20%
Pharmacology, Toxicology and Pharmaceutical Science
Antitumor Activity
20%
Bile Duct Cancer
100%
Bile Duct Carcinoma
20%
Biliary Tract Cancer
100%
Chemotherapy
40%
Disease
40%
Gallbladder Cancer
100%
Gemcitabine
100%
Malignant Neoplasm
100%
Neutropenia
20%
Overall Survival
20%
Oxaliplatin
100%
Phase II Trials
100%
Progression Free Survival
20%
Thrombocytopenia
20%